Valuation: Vitrolife AB

Market Cap 12.53B 1.25B 1.1B 1.04B 947M 1.78B 120B 1.79B 4.83B 61.28B 4.7B 4.59B 197B P/E 2026 *
25.4x
P/E 2027 * 20.6x
Enterprise Value 13.08B 1.31B 1.15B 1.09B 988M 1.85B 125B 1.87B 5.04B 63.96B 4.9B 4.8B 206B EV / Sales 2026 *
3.78x
EV / Sales 2027 * 3.37x
Free-Float
54.39%
Yield 2026 *
1.2%
Yield 2027 * 1.36%
Manager TitleAgeSince
Chief Executive Officer 52 2023-07-31
Director of Finance/CFO 55 2025-10-09
Chief Investment Officer 40 -
Director TitleAgeSince
Director/Board Member 63 2013-04-18
Chairman 70 2023-07-31
Chairman 55 -
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.68% - - 1.26B
-0.62%-0.39%+184.67%+495.36% 23.8B
+1.34%+11.28%+691.93%+117.71% 11.53B
-1.19%+7.51%-29.94%-14.23% 10.67B
-1.83%-0.99%+3.87% - 8.97B
-0.15%-0.37%+96.82%+43.39% 6.51B
-0.08%+1.06%-27.44%-21.96% 5.81B
-0.98%+3.05%+4.25%-9.16% 4.46B
+1.96%-5.39%+56.56%+61.68% 3.7B
-1.52%+3.35%-14.61%-26.50% 2.9B
Average -0.36%+2.10%+107.35%+80.79% 8.71B
Weighted average by Cap. -0.46%+3.78%+162.68%+191.12%

Financials

2026 *2027 *
Net sales 3.46B 345M 305M 288M 261M 490M 33.12B 495M 1.33B 16.91B 1.3B 1.27B 54.43B 3.71B 370M 327M 309M 280M 525M 35.51B 531M 1.43B 18.13B 1.39B 1.36B 58.36B
Net income 493M 49.17M 43.39M 41.06M 37.23M 69.81M 4.72B 70.49M 190M 2.41B 185M 181M 7.75B 609M 60.77M 53.63M 50.74M 46.02M 86.28M 5.83B 87.13M 235M 2.98B 228M 223M 9.58B
Net Debt 549M 54.81M 48.37M 45.77M 41.51M 77.82M 5.26B 78.58M 212M 2.69B 206M 201M 8.64B -26.74M -2.67M -2.36M -2.23M -2.02M -3.79M -256M -3.83M -10.3M -131M -10.02M -9.81M -421M
Logo Vitrolife AB
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-